Cart
sales@molnova.com
Juncusol
CAS No. 62023-90-9
Juncusol( —— )
Catalog No. M31446 CAS No. 62023-90-9
Juncusol shows anxiolytic and sedative activities, it shows anxiolytic activity at dosages of 10 mg/kg; it can induce caspase-3-mediated cytotoxicity in HT22 cells. Juncusol has anti-microbial activity, it shows significant activity against MRSA strains.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 790 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameJuncusol
-
NoteResearch use only, not for human use.
-
Brief DescriptionJuncusol shows anxiolytic and sedative activities, it shows anxiolytic activity at dosages of 10 mg/kg; it can induce caspase-3-mediated cytotoxicity in HT22 cells. Juncusol has anti-microbial activity, it shows significant activity against MRSA strains.
-
DescriptionJuncusol shows anxiolytic and sedative activities, it shows anxiolytic activity at dosages of 10 mg/kg; it can induce caspase-3-mediated cytotoxicity in HT22 cells. Juncusol has anti-microbial activity, it shows significant activity against MRSA strains.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number62023-90-9
-
Formula Weight266.3
-
Molecular FormulaC18H18O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Gypenoside XIII
Gypenoside XIII is belonging to the gypenosides. Gypenosides, extracted from Gynostemma pentaphyllum, protect against cardiovascular diseases, especially atherosclerosis.
-
HCH6-1
HCH6-1 is a competitive Formyl peptide receptor 1 (FPR1) antagonist.
-
APOL1-IN-1
APOL1-IN-1 is a potent inhibitor of apolipoprotein L1 (APOL1) that can be used to study the pathogenesis of focal segmental glomerulosclerosis (FSGS) and nondiabetic kidney disease (NDKD), facilitating research into these diseases.
